What Is Turkey Tail Mushroom? A Science-Based Introduction

Turkey Tail (Trametes versicolor)

10,684 patients

PSK, the pharmaceutical extract from turkey tail, is backed by three meta-analyses covering 10,684 cancer patients — more clinical trial data than any other medicinal mushroom compound.

Ma et al., Oncotarget, 2017

8,009

patients in gastric cancer meta-analysis (Oba 2007)

1,094

patients in colorectal meta-analysis (Sakamoto 2006)

2,000+

years of documented use in Chinese and Japanese medicine

Ma et al., Oncotarget, 2017

View as image ↗

In 1965, a Japanese chemical engineer noticed something that changed the course of mushroom research. A neighbor with stomach cancer had gone into remission. The engineer credited prolonged use of Yun Zhi tea — brewed from turkey tail mushroom. He brought the observation to his employer, Kureha Corporation. Researchers there began systematic work on the mushroom's compounds. Six years later, they isolated PSK. By 1977, Japan's Ministry of Health had approved it as an adjuvant cancer drug. By 2017, three independent meta-analyses had tested PSK in 10,684 cancer patients across 23 controlled trials.^[3]

No other medicinal mushroom compound has been tested in that many patients. Turkey tail (Trametes versicolor) sits in a category by itself.

This guide covers what the mushroom is, where its active compounds come from, what the trials actually found, and what you can realistically expect from the supplements sold in the US. The research has a 50-year head start on most fungi. Getting the full picture requires understanding what PSK is, how it differs from what's in the supplement aisle, and what the clinical trials were actually measuring.

What Turkey Tail Mushroom Is

Turkey tail (Trametes versicolor) is a polypore mushroom — a species that grows in shelf-like brackets on dead and dying hardwood logs. It is found on every inhabited continent. The scientific name translates roughly as "thin bracket of many colors," which describes the fruiting body accurately: a fan-shaped structure with concentric rings of brown, tan, gray, and white, resembling a wild turkey's fanned tail.

It is not edible in any culinary sense. The flesh is tough, leathery, and without meaningful flavor. Its value is entirely in the chemistry produced by the mycelium — the dense network of root-like threads that runs through decaying wood and is where PSK and PSP are synthesized.

Its compositional signature is unusually strong. In a 2023 review comparing six of the most commonly sold medicinal mushrooms, turkey tail carried the highest beta-glucan content of the group — 60.79 grams per 100 grams on a dry basis, against 35.3 for lion's mane, 20.0 to 25.3 for shiitake, 8.5 for chaga, and 3.79 for cordyceps.^[10]

In Chinese medicine it is called Yun Zhi (cloud mushroom), used as a Qi tonic for the spleen, stomach, and lungs for at least 2,000 years. In Japan it is Kawaratake (roof tile mushroom), used in traditional Kampo formulations. The Ming Dynasty Compendium of Materia Medica, compiled by Li Shizhen in 1596, records it as a longevity tonic. The full traditional history and its relationship to modern research is covered in Turkey Tail in Traditional Medicine: History and Modern Research.

The Discovery That Launched 50 Years of Research

The 1965 cancer observation reached researchers who could act on it. Kureha Corporation launched a systematic research program into Yun Zhi's chemistry. By 1971, they had isolated a specific protein-bound polysaccharide from a strain they designated CM-101. They named it PSK — polysaccharide K — and began clinical testing.

The compound is structurally distinctive. PSK is a proteoglucan — a beta-glucan carbohydrate backbone bound to a protein component that makes up roughly 25 to 38% of the molecule.^[10] That protein-bound architecture, rather than the polysaccharide alone, is what the pharmacology has consistently pointed to as the active unit.

In 1977, the Japanese Ministry of Health approved PSK under the brand name Krestin as an adjuvant cancer treatment — a therapy given alongside primary treatment to reduce recurrence. It went on to be used widely in Japan in combination with chemotherapy, and its clinical effectiveness has been documented across gastric, esophageal, colon, rectal, and lung cancer.^[4]

The parallel Chinese story began independently. In 1983, researchers selected a different T. versicolor strain (designated COV-1) and isolated a structurally related compound they named PSP (polysaccharide peptide). PSP is also a protein-bound polysaccharide built on a beta-glucan backbone, and it is described in the review literature as activating immune cells by increasing production of cytokines, chemokines, histamine, and prostaglandin E, and as reducing chemotherapy side effects such as fatigue, appetite loss, and vomiting.^[10] Chinese researcher Prof Qing-yao Yang developed PSP into a clinical product. China approved PSP in 1987.

Two different strains, two different compounds, developed by two national research programs, approved by two governments 10 years apart. Most articles treat PSK and PSP as interchangeable names for the same thing. They are not — and the difference shows up in the cells they act on and in how much clinical evidence stands behind each, as the next section sets out.

PSK, PSP, and the Broader Chemistry of Turkey Tail

PSK and PSP are the most-studied compounds from turkey tail, but they are not the whole picture.

Alongside its (1,3)(1,6)-beta-D-glucans, turkey tail carries a documented set of phenolic acids — p-hydroxybenzoic, protocatechuic, vanillic, and homogentisic — plus B vitamins and fatty acids including linoleic, oleic, stearic, and linolenic.^[10] The beta-glucan fraction is the parent class that PSK and PSP both belong to, and at 60.79 g/100 g dry basis it is the largest such fraction among the commonly sold medicinal mushrooms.

The phenolic fraction is credited with antioxidant activity, but that activity has been characterized mainly in laboratory assays rather than human trials. Its clinical significance is not established at anything like the level of PSK's cancer adjuvant evidence, and it should not be read as a second reason to take the mushroom.

The more consequential point is that PSK and PSP do not appear to act on the same cells. In mice, PSK behaves as a selective TLR2 agonist: its activation of dendritic cells and T cells is TLR2-dependent, and its antitumor effect disappears when CD8+ T cells or NK cells are depleted — but not when CD4+ T cells are.^[11] PSP, tested on resting human peripheral blood mononuclear cells, significantly increased monocytes (CD14+/CD16−) while proliferation of T cells, NK cells, and B cells was not significantly changed.^[12]

Two different compounds, two different cellular targets, established in two different experimental systems — one a mouse tumor model, the other human cells in culture. Neither has been tested head-to-head in people. Treating PSK and PSP as interchangeable is the most common error in writing about this mushroom.

For the full structural chemistry and the PSK-vs-PSP comparison, see Turkey Tail Bioactive Compounds: PSK, PSP, and Beta-Glucans and PSK vs. PSP: Turkey Tail's Two Star Compounds.

How Turkey Tail Activates the Immune System

The mechanisms through which PSK and PSP work are better characterized than for almost any other medicinal mushroom compound. That is partly because Kureha invested decades of research into understanding a pharmaceutical product it had approved.

A mechanism review by Maehara and colleagues identifies three pathways through which PSK affects cancer immunity:^[4]

The first is recovering suppressed immunity. Tumors often suppress the immune system using a signaling molecule called TGF-beta. PSK appears to partially reverse this suppression, restoring the immune system's ability to recognize and attack tumor cells.

The second is activating anti-tumor immune cells directly. PSK promotes the maturation of dendritic cells — the scouts that identify foreign material and direct the rest of the immune response. It also shifts the immune response toward the Th1 pattern, which is associated with anti-tumor activity, and triggers IL-15, a signal that activates NK cells.

The third is direct effects on tumor cells: PSK induces apoptosis (programmed cell death) in some tumor cell lines in laboratory conditions and may inhibit metastasis.

Guggenheim and colleagues reviewed the immunological roles of five major mushrooms in oncology — Agaricus blazei, Cordyceps sinensis, Grifola frondosa, Ganoderma lucidum, and Trametes versicolor.^[6] Their summary judgment is worth quoting precisely, because it is more restrained than the way it is usually paraphrased: for all five mushrooms, "an abundance of in vitro evidence exists that elucidates the anticancer immunological mechanisms," while human research is "preliminary" and "promising." The review did not rank the five species against each other. Turkey tail's claim to the strongest position rests not on that review but on the trial arithmetic — 10,684 patients is simply a larger number than any other mushroom compound has accumulated.

The only US Phase 1 human trial, by Torkelson and colleagues, tested a T. versicolor preparation in women with breast cancer at doses escalating up to 9 grams per day for six weeks after radiotherapy.^[5] Eleven were recruited; nine completed. CD8+ T cells (the cells that directly kill tumor cells) and CD19+ B cells increased in a dose-related pattern — but CD4+ T cells and CD16+56+ NK cell counts did not. At 6 grams per day, NK cell functional activity increased, and lymphocyte counts trended upward at 6 and 9 grams per day.

The only US human trial

Torkelson et al. (2012) · ISRN Oncology

Population

Women with breast cancer who had recently completed radiotherapy; 11 recruited, 9 completed, in cohorts of 3

Intervention

Oral Trametes versicolor preparation in divided daily doses for 6 weeks, escalating across cohorts at 3, 6, or 9 grams per day

Comparator

None — single-arm dose escalation, no placebo group

Finding

Nine adverse events were reported (7 mild, 1 moderate, 1 severe), which the authors judged consistent with good tolerability. Immune trends: dose-related increases in CD8+ T cells and CD19+ B cells, but not CD4+ T cells or CD16+56+ NK cells; increased NK cell functional activity at 6 g/day; increased lymphocyte counts at 6 and 9 g/day.

preliminary Nine participants, no control arm, and surrogate immune markers rather than a cancer outcome. This establishes tolerability up to 9 g/day. It cannot establish benefit.

Torkelson et al., ISRN Oncology, 2012 [ref 5]

Nine participants with no control arm cannot tell you whether immune cell increases translate to clinical benefit. What the trial does establish is that a whole-mushroom preparation is tolerable at doses well above typical supplement labels, and that measurable immune changes occur in human blood at those doses.

A separate in vitro study by Benson and colleagues tested turkey tail mycelium and its fermented substrate as separate fractions, rather than isolated PSK.^[8] The mycelium triggered robust induction of the CD69 activation marker on both lymphocytes and monocytes. The fermented substrate produced only minor CD69 induction — but it drove large, dose-dependent increases in cytokines including IL-2, IL-6, IL-10, IL-1ra, IFN-gamma, MIP-1alpha, G-CSF, and IL-8. The uncultured starting substrate did neither. The authors concluded that the bioactivity of a mycelium-based preparation is a combination of the mycelium and the fermented substrate it grew on.

One disclosure belongs with that result: the study was sponsored by Fungi Perfecti, LLC, a commercial producer of mushroom mycelium products. Four authors are employed by the sponsor, and a fifth — Paul Stamets — is the company's founder and owner and holds patents related to the work. That does not make the in vitro findings wrong, and the methods are reported in detail. It does mean the result should carry less weight than an equivalent finding from an independent laboratory, and it has not been replicated independently.

The practical reading is narrower than it is usually given. This is a cell-culture experiment showing that two fractions of a mycelium product each have activity. It is not evidence that mycelium-plus-substrate products work better in people than extracts do, because no human trial has compared them.

For the detailed immune mechanism, see Turkey Tail and Immune Health: How It Activates Your Defenses. For the receptor-level mechanism of how beta-glucans signal the immune system, see Mushroom Beta-Glucans and Immunity: The Complete Research Guide.

Three Meta-Analyses, One Picture: The Cancer Evidence Pyramid

No other medicinal mushroom has this kind of clinical trial foundation. Three independent meta-analyses have tested PSK in cancer patients, each covering a different primary cancer site. Assembled together, they tell a consistent story.

One point of arithmetic first, because it is routinely garbled. These three analyses are not additive. Ma's 10,684 patients across 23 trials is a network meta-analysis of gastrointestinal cancer that draws on much of the same trial literature Sakamoto and Oba had already pooled. The correct reading is that 10,684 is the largest single accounting of PSK trial patients, not the sum of three separate patient populations. What makes the picture convincing is not a bigger total — it is that three groups, using different statistical approaches on overlapping evidence, reached the same direction of effect.

Colorectal Cancer: 1,094 Patients

Sakamoto and colleagues analyzed three centrally randomized controlled trials testing PSK plus chemotherapy versus chemotherapy alone in patients with curatively resected colorectal cancer.^[1] Total enrollment: 1,094 patients.

Patients were followed for at least five years, and the analysis was intent-to-treat with no patient exclusions. Overall survival favored PSK: risk ratio 0.71 (95% CI 0.55–0.90, P=0.006). Disease-free survival also favored PSK: risk ratio 0.72 (95% CI 0.58–0.90, P=0.003).

Gastric Cancer: 8,009 Patients

Oba and colleagues analyzed 8 randomized controlled trials of PSK immunochemotherapy in gastric cancer patients — 8,009 patients total, making this the largest single-disease evidence base for any medicinal mushroom compound.^[2]

Overall survival: HR 0.88 (95% CI 0.79-0.98, P=0.018) favoring PSK. An HR of 0.88 means patients receiving PSK had a 12% lower hazard of dying during the follow-up period, and the result was statistically significant across 8 independent trials.

All Gastrointestinal Cancers: 10,684 Patients

Ma and colleagues conducted a network meta-analysis — a statistical method that compares multiple interventions simultaneously across trials — covering 23 RCTs, 13 intervention arms, and 10,684 patients with gastrointestinal cancers.^[3] PSK significantly increased 1-to-5-year overall survival and 1-to-7-year disease-free survival, with positive but non-significant trends at 6 and 7 years. Effects were clearest in the colorectal and gastric cancer subgroups. The network analysis found PSK combined with chemotherapy superior at 3-year and 5-year overall survival, and no increase in side effects was observed.

A 2023 scoping review by Dan and colleagues screened 2,202 records on medicinal mushrooms in gastric, breast, and colorectal cancer and reduced them to nine studies meeting inclusion criteria.^[9] Turkey tail (as Coriolus versicolor) was one of three species with human efficacy data in that final set, alongside shiitake (Lentinus edodes) and scaly wood mushroom (Agaricus sylvaticus). The review's own conclusion was cautious: more research with larger randomized samples is needed to ascertain the most efficacious dosages.

Evidence Ledger

Three Meta-Analyses, Three Cancer Sites, One Direction

Independent research groups, different primary tumour sites, different effect measures. Every value below 1.0 favours PSK added to chemotherapy. Assembled here because the agreement between them is the actual finding.

Sakamoto et al., 2006

Cancer Immunol Immunother [ref 1]

Cancer site

Colorectal

Patients

1,094

Trials pooled

3 centrally randomised RCTs

Overall survival (risk ratio)

0.71

95% CI 0.55–0.90

P = 0.006

Oba et al., 2007

Cancer Immunol Immunother [ref 2]

Cancer site

Gastric

Patients

8,009

Trials pooled

8 RCTs after central randomisation

Overall survival (hazard ratio)

0.88

95% CI 0.79–0.98

P = 0.018

Ma et al., 2017

Oncotarget [ref 3]

Cancer site

All gastrointestinal

Patients

10,684

Trials pooled

23 RCTs, 13 intervention arms

3- and 5-year overall survival

Superior

PSK + chemo vs chemo alone

Significant

The row that applies to all three

Every trial in every one of these meta-analyses used pharmaceutical-grade PSK (Krestin) at 3 grams per day, manufactured by Kureha Corporation from the CM-101 strain, given alongside chemotherapy after curative surgery. None tested a whole-mushroom supplement, and none tested PSK on its own as a treatment.

Sources: Sakamoto et al., Cancer Immunology, Immunotherapy, 2006 [ref 1]; Oba et al., Cancer Immunology, Immunotherapy, 2007 [ref 2]; Ma et al., Oncotarget, 2017 [ref 3]. Oba reported no significant heterogeneity across its eight trials (chi-square = 11.7 on 8 df; P = 0.16); Ma is registered as PROSPERO CRD42017065193 and found no increase in side effects with PSK.

The Substitution

What Was Tested vs. What Is On the Shelf

Same rows for both, so the swap is visible. The left column is the reason turkey tail is famous. The right column is what you can actually buy. They are not the same product, and the evidence does not travel between them.

What the evidence tested

Pharmaceutical PSK (Krestin)

What it is

PSK (Krestin) — a proteoglucan isolated from the CM-101 strain, manufactured by Kureha under pharmaceutical controls

Regulatory status

Licensed drug in Japan since 1977; approved as a cancer adjuvant

Dose studied

3 g/day, given alongside chemotherapy after curative surgery

Patients in RCTs

10,684 across 23 randomised controlled trials

Endpoint measured

Overall survival and disease-free survival at 1–7 years

Meta-analyses

Three, independently conducted

Available to you

No — not sold as a consumer product outside Japan

What the evidence gets used to sell

US turkey tail supplements

What it is

Dried whole fruiting body, hot water extract, or mycelium grown on grain substrate

Regulatory status

Dietary supplement in the US; no FDA approval to treat any condition

Dose studied

No dose established by any clinical trial for a cancer outcome

Patients in RCTs

9, in a single-arm Phase 1 safety study with no control group

Endpoint measured

Immune cell counts and activation markers; microbiome composition

Meta-analyses

None

Available to you

Yes — widely, in most health stores

This is not an argument that turkey tail supplements do nothing. It is an argument about what has been demonstrated. The right-hand column has real evidence behind it — a Phase 1 tolerability trial, a randomised microbiome trial, and a strong compositional profile with the highest beta-glucan content among six commonly sold medicinal mushrooms at 60.79 g per 100 g dry basis. What it does not have is a single randomised trial measuring a cancer outcome. Anyone quoting the 10,684 figure on a supplement page is borrowing the left column to describe the right one.

Sources: Sakamoto et al., 2006 [ref 1]; Oba et al., 2007 [ref 2]; Ma et al., Oncotarget, 2017 [ref 3]; Maehara et al., Surgery Today, 2012 [ref 4]; Torkelson et al., ISRN Oncology, 2012 [ref 5]; Benson et al., BMC Complementary and Alternative Medicine, 2019 [ref 8]; Łysakowska et al., Molecules, 2023 [ref 10].

What these trials were actually measuring

All three meta-analyses used pharmaceutical-grade PSK (Krestin), manufactured by Kureha Corporation, at 3 grams per day. This matters for interpreting the evidence.

PSK (Krestin) is Kureha's proprietary extract from the CM-101 strain, manufactured under pharmaceutical quality controls. It is a licensed drug in Japan, not a dietary supplement. It is not available as a consumer product outside Japan. Turkey tail supplements sold in health stores in the US contain dried whole mushroom, mycelium extract, or hot water extract — not Krestin.

This is the single most important caveat in the turkey tail literature, and it is the one most often left out. The meta-analysis results apply to a specific pharmaceutical preparation at a specific dose. Whether lower doses of whole-mushroom supplements produce similar benefits has not been tested in randomized controlled trials.

That is not a reason to dismiss the supplement evidence. It is a reason to be clear about what has and has not been demonstrated.

Fact Check

The 10,684-patient transfer

The claim

“Turkey tail supplements are backed by more than 10,000 patients in randomized clinical trials.”

Supplement listings and roundup articles that cite the PSK meta-analyses on pages selling whole-mushroom capsules.

What research shows

Misleading

The 10,684 patients are real, and every one of them received pharmaceutical-grade PSK (Krestin) at 3 g/day — a licensed Japanese drug manufactured by Kureha from the CM-101 strain, alongside chemotherapy, after curative surgery for gastrointestinal cancer.

No randomized trial has tested a US retail turkey tail supplement against a cancer outcome. The evidence is not fake and it is not being misquoted — it is being transferred to a product it was never collected on. The honest version of the claim is that the mushroom's pharmaceutical extract has a large trial base, and that the supplement is a different preparation whose clinical effects are untested.

Sakamoto et al., Cancer Immunol Immunother, 2006 [ref 1]; Oba et al., 2007 [ref 2]; Ma et al., Oncotarget, 2017 [ref 3]

For the detailed cancer evidence review, see Trametes versicolor: The Most-Studied Medicinal Mushroom for Cancer. For the pharmaceutical pathway, see Turkey Tail and Cancer: 40 Years of Research Reviewed and PSK (Krestin): Japan's Approved Mushroom Cancer Drug. For how mushrooms compare as cancer adjuvants across species, see How Mushrooms Support Cancer Patients: Mechanisms and Evidence.

The Gut Microbiome Evidence

The cancer evidence dominates turkey tail research, but there is a second, distinct line of evidence that gets far less attention: turkey tail polysaccharides appear to act as prebiotics, shaping the composition of gut bacteria.

Pallav and colleagues conducted the first randomized controlled trial testing this in humans, published in 2014.^[7] Twenty-four healthy volunteers were randomized to three arms — PSP from Trametes versicolor, amoxicillin, or no treatment as a control. Twenty-two completed. Stool was analyzed by bTEFAP, a tag-encoded amplicon pyrosequencing method, on seven occasions over eight weeks in the treatment arms.

The headline result is that PSP produced clear and consistent microbiome changes of the kind a prebiotic would be expected to cause — the first in vivo demonstration of that effect for PSP in humans. Amoxicillin, by contrast, caused substantial disruption, most notably an increase in Escherichia/Shigella, and those changes were still present 42 days after the antibiotic course ended.

The gut microbiome trial

Pallav et al. (2014) · Gut Microbes

Population

24 healthy volunteers randomized to three arms; 22 of 24 completed the protocol

Intervention

Polysaccharopeptide (PSP) from Trametes versicolor, versus amoxicillin, versus no treatment

Comparator

Untreated control arm plus an active antibiotic comparator

Finding

PSP led to clear and consistent microbiome changes consistent with its activity as a prebiotic. Amoxicillin caused substantial microbiome change — most notably an increase in Escherichia/Shigella — that persisted to the end of the study, 42 days after therapy ended. The authors also report that baseline microbiomes remained stable and tended to overshadow the treatment effects.

preliminary Small, in healthy volunteers, with no clinical endpoint. The authors' own caveat — that individual baseline microbiome identity outweighed what either treatment did — is the most important sentence in the paper.

Pallav et al., Gut Microbes, 2014 [ref 7]

The trial matters for what it is, not for more than it is. It is one of very few human randomized trials on any mushroom compound and the gut microbiome, it tested PSP specifically rather than a generic extract, and it included both an antibiotic comparator and an untreated control. Its endpoints are microbial composition, not symptoms, digestion, or disease.

The proposed mechanism is fermentation. Gut bacteria ferment undigested polysaccharides, producing short-chain fatty acids that feed the gut lining and shift conditions in favor of some species over others — the same general mechanism as fiber-based prebiotics such as inulin or FOS. For turkey tail polysaccharides this remains a mechanistic hypothesis supported by compositional change, not a demonstrated clinical outcome.

See How Turkey Tail Changes Gut Bacteria Composition for the full microbiome evidence, and Turkey Tail and the Gut-Immune Connection for how the microbiome effects connect to immune function. For the broader context on mushroom polysaccharides as prebiotics, see Mushrooms as Prebiotics: How Fungal Polysaccharides Feed Beneficial Bacteria.

The Supplement Reality: What You Can Actually Buy

Understanding what the clinical trials measured makes the supplement landscape clearer — and more honest.

PSK (Krestin) is manufactured exclusively by Kureha Corporation from the CM-101 strain under pharmaceutical conditions. It is not available as a consumer supplement anywhere outside Japan. If a supplement label claims to contain PSK, that claim requires scrutiny.

PSP is found in some Chinese herbal preparations and supplement products. The evidence base for PSP in cancer is more limited than for PSK — PSP has not been tested in meta-analyses of the same scale. The Pallav 2014 gut microbiome RCT used PSP specifically, which gives it a distinct evidence position in the prebiotic area.

US turkey tail supplements typically contain dried whole fruiting body, hot water extract, or mycelium extract from T. versicolor. These preparations contain a range of compounds, including beta-glucans and the phenolic acids documented in the compositional literature.^[10] What they do not contain is Krestin at 3 g/day — the compound and dose used in the cancer meta-analyses.

Beta-glucan content is the most meaningful quality marker for immune-focused turkey tail products, because it is the fraction PSK and PSP both belong to and it is measurable. Reported whole-mushroom values reach about 61% by dry weight, so a product disclosing a credible beta-glucan percentage is telling you something real about its raw material. Products that disclose only "polysaccharides" are not: that figure routinely includes starch from the growing substrate and is not a beta-glucan measurement.

The fruiting body versus mycelium question that applies to most medicinal mushrooms also applies to turkey tail. The Benson 2019 in vitro data suggests the mycelium and its fermented substrate contribute different activities rather than one being simply better — but that was a sponsor-funded cell-culture study, and no human trial has compared preparation types against any outcome.^[8]

For a complete framework on evaluating supplement quality across medicinal mushrooms, see How to Choose a Mushroom Supplement: A Buyer's Guide.

Safety: What Decades of Clinical Trials Recorded

Turkey tail has one of the best-characterized safety profiles of any medicinal mushroom, simply because it has been tested in clinical trials for 50 years.

Torkelson's Phase 1 trial concluded that up to 9 grams per day of a T. versicolor preparation is safe and tolerable in women with breast cancer after primary treatment.^[5] The precise record is worth stating rather than rounding off: nine adverse events were reported across the trial — seven mild, one moderate, and one severe. The authors judged that profile consistent with good tolerability. It is not the same as "no adverse events," and articles that report it that way are overstating a small trial.

The Japanese PSK trials used 3 grams per day across thousands of patients in combination with chemotherapy. The Ma network meta-analysis specifically assessed safety outcomes across its 23 trials and found no increase in side effects with PSK.^[3]

Some individuals taking higher doses of whole turkey tail supplements report mild and transient gastrointestinal symptoms — loose stools or nausea. This appears dose-dependent.

There is no established dosing range for whole-mushroom turkey tail supplements derived from clinical trials. The 3 g/day dose from the PSK trials reflects the pharmaceutical product, not dried whole mushroom. Supplement products vary in what they deliver per gram depending on extraction method, beta-glucan content, and starting material.

Before You Act On This

Moderate

This is a cancer-adjuvant literature, and it is not a treatment recommendation

Concern

Most of the human evidence in this article comes from cancer patients receiving PSK alongside chemotherapy after curative surgery, or from breast cancer survivors after radiotherapy. Turkey tail compounds measurably alter immune signaling — PSK acts through TLR2 and depends on CD8+ T cells and NK cells in animal models, and PSP shifts monocyte populations in human cells. That is precisely why it matters who is taking it.

What the research says

Nothing here is a recommendation to treat, prevent, or cure any condition, and no turkey tail product is approved to treat any condition in the United States. Delaying or substituting conventional cancer treatment on the basis of this evidence would invert what the trials actually tested: PSK was always an addition to chemotherapy, never a replacement for it.

Particularly relevant for: People undergoing cancer treatment, taking immunosuppressants or anticoagulants, preparing for surgery, pregnant or breastfeeding, or immunocompromised

What to do

This article is educational and is not medical advice. Talk to your oncologist or a qualified healthcare provider before adding any mushroom supplement, especially during active treatment.

Torkelson et al., ISRN Oncology, 2012 [ref 5]; Ma et al., Oncotarget, 2017 [ref 3]; Lu et al., Clin Cancer Res, 2011 [ref 11]

Evidence Position

1. Cell studiescompleted

   Extensive. PSP increases monocytes in resting human PBMC while leaving T, NK, and B cell proliferation unchanged (Sekhon 2013); mycelium and fermented substrate each activate immune cells in vitro (Benson 2019, sponsor-funded).

2. Animal studiescompleted

   PSK identified as a selective TLR2 agonist; oral PSK inhibits breast tumor growth in neu transgenic mice, dependent on CD8+ T cells and NK cells (Lu 2011).

3. Human case reportscompleted

   Long clinical use in Japan since the 1977 Krestin approval, with no pattern of serious organ toxicity reported across the trial literature.

4. Small human trialscompleted

   Phase 1 dose escalation in 9 breast cancer survivors up to 9 g/day (Torkelson 2012); 24-volunteer randomized microbiome trial of PSP (Pallav 2014).

5. Large randomised trialscompleted

   23 RCTs of pharmaceutical PSK in gastrointestinal cancer, all as an adjunct to chemotherapy after curative resection.

6. Meta-analysiscompleted

   Three: colorectal, 1,094 patients (Sakamoto 2006); gastric, 8,009 patients (Oba 2007); network meta-analysis, 10,684 patients (Ma 2017).

Turkey tail is the one medicinal mushroom that has climbed every rung, which is why it gets called the most-evidenced. The ladder describes PSK — a licensed Japanese pharmaceutical at 3 g/day. For the whole-mushroom supplement sold in the US, the top three rungs are empty: no large RCT and no meta-analysis has ever tested it against a clinical outcome.

Sakamoto et al., 2006 [ref 1]; Oba et al., 2007 [ref 2]; Ma et al., 2017 [ref 3]; Torkelson et al., 2012 [ref 5]; Pallav et al., 2014 [ref 7]; Benson et al., 2019 [ref 8]; Lu et al., 2011 [ref 11]; Sekhon et al., 2013 [ref 12]

Explore the Full Turkey Tail Research

This pillar article is part of a dedicated cluster covering every dimension of turkey tail research. Each article below goes deeper on a specific topic:

• Turkey Tail Bioactive Compounds: PSK, PSP, and Beta-Glucans — structural chemistry, molecular weights, strain origins, phenolic compounds
• PSK vs. PSP: Turkey Tail's Two Star Compounds — the CM-101 vs COV-1 strain story, sugar composition differences, evidence asymmetry, and the availability problem
• Trametes versicolor: The Most-Studied Medicinal Mushroom for Cancer — the three meta-analyses in depth and what they mean for clinical practice
• Turkey Tail and Cancer: 40 Years of Research Reviewed — the full research timeline from 1965 to present
• PSK (Krestin): Japan's Approved Mushroom Cancer Drug — the pharmaceutical approval pathway and why PSK cannot be replicated in supplement form
• Turkey Tail and Immune Health: How It Activates Your Defenses — NK cells, T cell differentiation, dendritic cell maturation in depth
• Turkey Tail in Traditional Medicine: History and Modern Research — Yun Zhi, Kawaratake, Li Shizhen's Compendium, and the 1965 discovery story
• How Turkey Tail Changes Gut Bacteria Composition — Pallav 2014 in depth and the prebiotic evidence
• Turkey Tail and the Gut-Immune Connection — how microbiome changes translate to immune system effects

The Bottom Line

Turkey tail mushroom (Trametes versicolor) has the largest clinical trial base of any medicinal mushroom for cancer adjuvant use: its pharmaceutical extract PSK was tested in three meta-analyses covering 10,684 patients and approved by the Japanese Ministry of Health in 1977. A related but distinct compound from the same mushroom, PSP, shifted gut microbiome composition in a human randomized trial. The gap between that trial evidence and what is available in consumer supplements is significant and largely unreported: PSK (Krestin) is a proprietary Japanese pharmaceutical given at 3 g/day alongside chemotherapy, not a supplement ingredient, and no US retail turkey tail product has been tested against a clinical outcome.

Frequently Asked Questions

What is turkey tail mushroom good for?

Turkey tail has the largest clinical trial base of any medicinal mushroom for cancer adjuvant use: three meta-analyses covering 10,684 patients show that PSK, its pharmaceutical extract, improves survival when added to chemotherapy after curative surgery for gastric and colorectal cancer. A randomized trial in 24 healthy volunteers also found that PSP from turkey tail shifted the gut microbiome in a direction consistent with prebiotic activity. Both results describe specific preparations — pharmaceutical PSK at 3 g/day and PSP respectively — not the whole-mushroom supplements sold in US stores, which have not been tested against a clinical outcome.

Is turkey tail mushroom FDA approved?

Turkey tail mushroom supplements are regulated as dietary supplements under US law and do not require FDA approval. The pharmaceutical extract PSK (Krestin) is approved in Japan and China as a cancer adjuvant drug, but that approval does not apply in the United States. No turkey tail mushroom product has received FDA approval as a drug. A Phase 1 clinical trial in breast cancer survivors (Torkelson 2012) established safety at up to 9 grams per day, but this was not a drug approval pathway.

What does turkey tail mushroom do for the immune system?

Turkey tail's compounds PSK and PSP appear to activate different arms of the immune system. PSK promotes dendritic cell maturation, corrects Th1/Th2 imbalance, promotes IL-15 production, and helps reverse tumor-induced immune suppression; in mice it acts as a selective TLR2 agonist whose antitumor effect depends on CD8+ T cells and NK cells. PSP, tested on resting human blood cells, increased monocytes while leaving T, NK, and B cell proliferation unchanged. In a Phase 1 human trial, CD8+ T cells and CD19+ B cells rose in a dose-related pattern and NK cell functional activity increased at 6 grams per day. Most of this evidence comes from laboratory and animal work or from trials in cancer patients receiving chemotherapy, not from healthy people taking supplements.

Can you eat turkey tail mushroom?

Turkey tail mushroom is not edible as food. The fruiting body is thin, tough, leathery, and lacks culinary value. It is consumed as a supplement — in capsules, powders, or teas made from hot water extraction of the dried fruiting body or mycelium. The hot water extraction is important because turkey tail's active polysaccharides are water-soluble but not easily broken down by the digestive system if consumed as raw dried powder.

What is the difference between turkey tail and Trametes versicolor?

Turkey tail is the common name; Trametes versicolor is the scientific name for the same species. The genus Trametes was previously classified as Coriolus, which is why older literature refers to Coriolus versicolor. PSK is sometimes sold under the name "Coriolus extract." All three names — turkey tail, Trametes versicolor, and Coriolus versicolor — refer to the same mushroom species. Yun Zhi (Chinese) and Kawaratake (Japanese) are additional traditional names for the same fungus.

Is turkey tail safe to take every day?

The best available human data covers six weeks, not years of daily use. A Phase 1 trial found up to 9 grams per day tolerable in nine breast cancer survivors over six weeks, with nine adverse events recorded (seven mild, one moderate, one severe). The Japanese PSK trials used 3 grams per day of a pharmaceutical extract in cancer patients alongside chemotherapy, and a network meta-analysis of 23 trials found no increase in side effects with PSK. Some people taking higher doses of whole-mushroom supplements report mild, transient gastrointestinal symptoms. No trial has established a safe upper limit or a long-term daily dose for whole-mushroom turkey tail supplements, and this is not medical advice — check with your clinician, particularly if you take prescription medication.

What conditions does turkey tail mushroom treat?

Turkey tail's primary evidence base is cancer adjuvant therapy — specifically, improving survival when PSK is added to chemotherapy in gastric and colorectal cancer. This evidence comes from large clinical trials and is specific to pharmaceutical-grade PSK, not to consumer supplements. Secondary evidence covers immune activation (established in human trials) and gut microbiome effects (one human RCT showing prebiotic activity). Turkey tail is not approved to treat any condition in the United States. The clinical trial evidence is from Japan and China using regulated pharmaceutical products.

Sources & References

1. 1RTHM-00200·Sakamoto, Junichi et al. (2006). “Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials..” Cancer immunology.Study breakdown →PubMed →↩
2. 2RTHM-00226·Oba, Koji et al. (2007). “Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer..” Cancer immunology.Study breakdown →PubMed →↩
3. 3RTHM-00895·Ma, Yan et al. (2017). “Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? a systematic review and network meta-analysis..” Oncotarget.Study breakdown →PubMed →↩
4. 4RTHM-00475·Maehara, Yoshihiko et al. (2012). “Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives..” Surgery today.Study breakdown →PubMed →↩
5. 5RTHM-00267·Torkelson, Carolyn J et al. (2012). “Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer..” ISRN oncology.Study breakdown →PubMed →↩
6. 6RTHM-00323·Guggenheim, Alena G et al. (2014). “Immune Modulation From Five Major Mushrooms: Application to Integrative Oncology..” Integrative medicine (Encinitas.Study breakdown →PubMed →↩
7. 7RTHM-00630·Pallav, Kumar et al. (2014). “Effects of polysaccharopeptide from Trametes versicolor and amoxicillin on the gut microbiome of healthy volunteers: a randomized clinical trial..” Gut microbes.Study breakdown →PubMed →↩
8. 8RTHM-01034·Benson, Kathleen F et al. (2019). “The mycelium of the Trametes versicolor (Turkey tail) mushroom and its fermented substrate each show potent and complementary immune activating properties in vitro..” BMC complementary and alternative medicine.Study breakdown →PubMed →↩
9. 9RTHM-01682·Dan, Amit et al. (2023). “Therapeutic Effects of Medicinal Mushrooms on Gastric, Breast, and Colorectal Cancer: A Scoping Review..” Cureus.Study breakdown →PubMed →↩
10. 10RTHM-00843·Łysakowska, Paulina et al. (2023). “Medicinal Mushrooms: Their Bioactive Components, Nutritional Value and Application in Functional Food Production-A Review..” Molecules (Basel.Study breakdown →PubMed →↩
11. 11RTHM-00419·Lu, Hailing et al. (2011). “Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells..” Clinical cancer research : an official journal of the American Association for Cancer Research.Study breakdown →PubMed →↩
12. 12RTHM-00552·Sekhon, Bhagwant Kaur et al. (2013). “PSP activates monocytes in resting human peripheral blood mononuclear cells: immunomodulatory implications for cancer treatment..” Food chemistry.Study breakdown →PubMed →↩